Cargando…

Plasma fractalkine contributes to systemic myeloid diversity and PD‐L1/PD‐1 blockade in lung cancer

Recent studies highlight the importance of baseline functional immunity for immune checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in a cohort of non‐small‐cell lung cancer patients undergoing PD‐L1/PD‐1 blockade immunotherapy. Responders show high baseline mye...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bocanegra, Ana, Fernández‐Hinojal, Gonzalo, Ajona, Daniel, Blanco, Ester, Zuazo, Miren, Garnica, Maider, Chocarro, Luisa, Alfaro‐Arnedo, Elvira, Piñeiro‐Hermida, Sergio, Morente, Pilar, Fernández, Leticia, Remirez, Ana, Echaide, Miriam, Martinez‐Aguillo, Maite, Morilla, Idoia, Tavira, Beatriz, Roncero, Alejandra, Gotera, Carolina, Ventura, Alfonso, Recalde, Nerea, Pichel, José G, Lasarte, Juan José, Montuenga, Luis, Vera, Ruth, Pio, Ruben, Escors, David, Kochan, Grazyna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398648/ https://www.ncbi.nlm.nih.gov/pubmed/37366231 http://dx.doi.org/10.15252/embr.202255884

Ejemplares similares

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Understanding LAG-3 Signaling
por: Chocarro, Luisa, et al.
Publicado: (2021)

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
por: Bocanegra, Ana, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

CAR-T Cells for the Treatment of Lung Cancer
por: Chocarro, Luisa, et al.
Publicado: (2022)

Hyperprogressive Disease: Main Features and Key Controversies
por: Arasanz, Hugo, et al.
Publicado: (2021)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
por: Zuazo, Miren, et al.
Publicado: (2019)

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy
por: Zuazo, Miren, et al.
Publicado: (2020)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Clinical landscape of LAG-3-targeted therapy
por: Chocarro, L., et al.
Publicado: (2022)

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets
por: Blanco, Ester, et al.
Publicado: (2021)

Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors
por: Blanco, Ester, et al.
Publicado: (2023)

Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
por: Chocarro, Luisa, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
por: Hernandez, Carlos, et al.
Publicado: (2020)

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
por: Echaide, Miriam, et al.
Publicado: (2022)

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics
por: Arasanz, Hugo, et al.
Publicado: (2020)

PD1 signal transduction pathways in T cells
por: Arasanz, Hugo, et al.
Publicado: (2017)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
por: Echaide, Miriam, et al.
Publicado: (2023)

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8(+) T Cells
por: Baraibar, Iosune, et al.
Publicado: (2020)

How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells
por: Garnica, Maider, et al.
Publicado: (2022)

How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells
por: Aiello, Anna, et al.
Publicado: (2022)

IGF1R acts as a cancer-promoting factor in the tumor microenvironment facilitating lung metastasis implantation and progression
por: Alfaro-Arnedo, Elvira, et al.
Publicado: (2022)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Metabolic dyshomeostasis induced by SARS-CoV-2 structural proteins reveals immunological insights into viral olfactory interactions
por: Lachén-Montes, Mercedes, et al.
Publicado: (2022)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD
por: de la Fuente-Fernández, Raúl
Publicado: (2013)

The multi-specific V(H)-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
por: Edwards, Carolyn J., et al.
Publicado: (2021)

Fractalkine Depresses Cardiomyocyte Contractility
por: Taube, David, et al.
Publicado: (2013)

Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma
por: Gurler, Hilal, et al.
Publicado: (2015)

Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition
por: Arasanz, Hugo, et al.
Publicado: (2020)

Digital quantitative assessment of PD-L1 using digital spatial profiling
por: Gupta, Swati, et al.
Publicado: (2020)

The roles of fractalkine signaling in neurodegenerative disease
por: Lamb, Bruce
Publicado: (2012)

Correction: Fractalkine Depresses Cardiomyocyte Contractility
por: Taube, David, et al.
Publicado: (2013)

Neuroinflammation and fractalkine signaling in Alzheimer’s disease
por: Finneran, Dylan J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_p412iqh0pm0v0nisfdds9buv2v